AlphMol obtained approval from Chinese and American regulatory bodies for auto immune diseases treatment

Monday, June 2, 2025 @ 12:00 am

AlphMol obtained IND approval from both Chinese CDE and American FDA for the leading auto immune pipeline.

This drug candidate AM-001 is an oral small molecule, targeting MRGPRX2 receptor to treat different auto immune diseases including atopic dermatitis, urticaria and potentially others. AM-001 is a very safe drug candidate with the safety margin >600 folds in the GLP tox study in monkey. Its outstanding in vivo efficacies were verified by different animal models. Related clinical trial will be started soon.

About the target MRGPRX2
MRGPRX2 is a clinically proof-of-concepted G protein-coupled receptor which is on the surface of mast cell. It was distributed abandonly in the skin, adipose tissue as well as intestinal tract. The receptor is activated by a broad spectrum of ligands that are prevalent during inflammation. Targeting MRGPRX2 has great potential across an array of chronic inflammatory diseases and play a role in mitigating neurogenic inflammation. It would be a very attractive alternative to nowadays biologics treatment.

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We regularly detect fraudulent emails attempting to steal your passwords — both personal and for our systems — through phishing attacks. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals
October 8, 2024

InSphero and Brenus Pharma: 3D tumor spheroids mimicking in vivo human colorectal cancer conditions

Brenus Pharma, a French biotech developing next-generation first-in-class immunotherapies, and InSphero, a Swiss leader in 3D cell-based assay technologies, presented promising data at the European Association for Cancer Research 2025 annual congress. These data confirm the use of 3D tumor spheroids for potency testing of STC-1010, Brenus’ lead candidate for colorectal cancer.
June 19, 2025

Pharvaris highlights their drugs potential to prevent and treat bradykinin-mediated angioedema attacks

Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced a summary of data that were presented at the European Academy of Allergy and Cl
June 16, 2025

HGF recognized for 7th year in a row by Financial Times

HGF has once again been ranked ‘Gold’ across all six bands in the Financial Times Special Report – Europe’s Leading Patent Law Firms 2025.
June 12, 2025

Leman Biotech treats first systemic lupus erythematosus patient

Leman Biotech Co., Ltd. ("Leman Biotech"), a clinical-stage biotechnology company focused on the research, development, production, and commercialization of innovative metabolic immunotherapies, announced a significant clinical progress made in its investigator-initiated trial (IIT) for metabolically armed CD19 CAR-T cell therapy (Meta10-19 injection). The first enrolled systemic lupus erythematos
June 12, 2025

Pharvaris: Data supports clinical development for bradykinin-mediated angioedema drug

Deucrictibant data shows single-dose durability without symptom reoccurrence in the majority of HAE attacks treated First-ever bradykinin B2 receptor mechanism-on-mechanism prophylactic/on-demand data supports potential for deucrictibant portfolio Clinically validated biomarker assay has potential to eventually expand treatment opportunities of deucrictibant into additional forms of bradykinin-med
June 2, 2025